Drug class
Programmed Death Ligand-1 Blocker
Mechanism of action
Programmed Death Ligand-1-directed Antibody Interactions
General use cases
- Carcinoma, Transitional Cell
- Carcinoma, Merkel Cell
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
